holdemodds| Watson Biotech is committed to cutting costs and improving quality, and the expansion of the vaccine market helps industry growth

Watson Biological sales expense rate maintains the industry averageHoldemoddsCommitted to increasing revenue, reducing expenditure, improving quality and increasing efficiency]

April thirteenthHoldemoddsWatson Biology (300142) said on the interactive platform that the company's sales expense rate was in line with comparable companies in the same industry. Watson Biology promises to continue to promote related work such as increasing revenue and reducing expenditure, improving quality and increasing efficiency. The enterprise points out that the cost input should be adapted to the company's development stage, strategic layout, market competition and industry maturity.

At present, the market space of China's vaccine industry is large, and the overseas market is also full of opportunities. Watson Biology, which is in the stage of market expansion at home and abroad, will increase the investment of resources to ensure the long-term development of the enterprise in the future.

Hexun self-selected Stock Writer risk Tip: the above content is only the views of the author or guest, does not represent any position of Hexun, and does not constitute any investment advice related to Hexun. Before making any investment decision, investors should consider the risk factors related to investment products according to their own circumstances and consult professional investment advisers if necessary. Hexun tries its best but cannot confirm the authenticity, accuracy and originality of the above content, and Hexun does not make any guarantee or commitment.

Tags:

Prev: 100handvideopokerfree|大众汽车中国投资激增：40款新车型亮相，半数绿能，2030年30款纯电竞逐
Next: gaplus| Dajia Property and Casualty Insurance received two consecutive fines in one week. Last year, it lost 345 million yuan in net profit, and its comprehensive risk rating rose to BB.